The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIMI Regulatory News (IMI)

Share Price Information for IMI (IMI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,752.00
Bid: 1,756.00
Ask: 1,757.00
Change: -1.00 (-0.06%)
Spread: 1.00 (0.057%)
Open: 1,754.00
High: 1,774.00
Low: 1,752.00
Prev. Close: 1,753.00
IMI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

8 Nov 2022 07:00

RNS Number : 5895F
IMI PLC
08 November 2022
 

8 November 2022

Strategic execution delivering sustainable, profitable growth

Full year EPS guidance increased to 103p - 106p

IMI, the specialist engineering company, issues the following Interim Management Statement which covers results for the third quarter from 1 July to 30 September 2022.

Roy Twite, Chief Executive, commented:

"Our unifying purpose-led strategy [Breakthrough Engineering for a better world] continues to underpin sustainable, profitable growth. We are creating value by increasing customer intimacy, driving market-led innovation and reducing complexity. These actions have allowed us to generate strong growth in the order book and revenues as well as improved margins year to date. Given the continued momentum in the business, based on current market conditions, we are upgrading our EPS guidance for the full year to 103p to 106p and remain confident in delivering our Group growth targets and operating margin target of 20% through the cycle over time."

Continued momentum in Q3

IMI has delivered another strong performance with its seventh consecutive quarter of organic growth. Third quarter Group organic revenue growth was up 4% compared to the same period last year and 10% higher on an adjusted basis.

Good momentum in our Growth Hub and Sprint Teams continues to drive growth and cultural alignment through the business. We now expect to deliver over £40m of orders from these projects in 2022.

Integration of our recent acquisitions is progressing well, delivering synergies in line with our business cases.

Our restructuring programmes remain on track to deliver £10m of benefits for the full year, £20m of benefits in 2023 and £20m in future years, with no changes to expected delivery costs.

We remain confident in delivering our Group growth targets and operating margin target of 20% through the cycle over time.

Divisional overview

IMI Precision's organic revenue growth was 3% in the third quarter and adjusted revenue growth was 16% versus the same period in 2021. Precision Fluid OEM delivered strong third quarter organic growth of 9%, with Industrial Automation and Transportation organic growth both 1%.

IMI Critical's order book at the end of the period was 11% higher than the same period last year, reflecting strong demand in LNG, Oil & Gas, and Power. Organic order intake in the period was up 21% on prior year, up 10% year to date, driven by continued strength in Aftermarket and improved Oil & Gas activity within New Construction. Aftermarket orders increased 24% in the period with strong growth in Refining & Petrochemical. IMI Critical organic revenue in the three months to the end of September was up 6% compared to the third quarter of 2021.

IMI Hydronic revenue in the third quarter was 3% higher on an organic basis, when compared to the third quarter of last year.

 

Heatmiser acquisition

IMI today announced the proposed acquisition of Heatmiser UK Ltd ("Heatmiser") for an enterprise value of £110m, with up to a further £8m based on Heatmiser's future financial performance. Heatmiser will become part of IMI Hydronic.

The proposed acquisition of Heatmiser is fully aligned with IMI's strategy and purpose of [Breakthrough Engineering for a better world] and represents an opportunity to accelerate our growth in smart buildings. Adjacent to IMI Hydronic's existing HVAC product offerings, Heatmiser will provide an attractive entry point into connected residential thermostatic control, a fast-growing market where Heatmiser is already a UK leader. There are significant opportunities to leverage IMI Hydronic's strong brand and market presence to scale Heatmiser's offering across Europe, as well as leverage Heatmiser's proven connected technology capabilities across existing and new IMI products.

In the financial year to December 2022, Heatmiser is expected to generate revenues of c.£22.5m. The headline enterprise value represents c.12x 2022 estimated adjusted EBITDA and is expected to deliver returns in line with IMI's strict acquisition criteria. Closing is expected before year end.

Exchange rates

If average exchange rates for October 2022 of US$1.13 and €1.15 remain constant for the remainder of the year, they would positively impact both revenue and adjusted operating profit by 4% in the 2022 full year when compared to 2021.

Outlook

Given the continued momentum in the business, based on current market conditions, we now expect 2022 full year adjusted EPS to be in the range of 103p to 106p.

We continue to expect IMI Precision and IMI Hydronic 2022 organic revenues to be higher than in 2021, with IMI Precision margins higher and IMI Hydronic margins slightly higher. We now expect that IMI Critical's 2022 adjusted revenue will be slightly higher than in 2021, with margins in line with 2021.

Net Debt / EBITDA is estimated to be around 1.8x at the year end.

Preliminary results

 

IMI looks forward to presenting its preliminary results announcement for the year ending 31 December 2022 on 3 March 2023.

 

Enquiries

Luke Grant

IMI

Tel: +44 (0)7866 148 374

Matt Denham

Headland PR

Tel: +44 (0)7551 825 496

A conference call for analysts and investors will be held at 08:30 GMT today to discuss this statement. To access the call, please register using the link:

https://www.netroadshow.com/events/login?show=07816f99&confId=43248

 

Notes

IMI plc, the specialist engineering company, designs, manufactures and services highly engineered products that control the precise movement of fluids. Its innovative technologies, built around valves and actuators, enable vital processes to operate safely, sustainably, cleanly, efficiently and cost effectively. IMI employs around 10,000 people, has manufacturing facilities in 19 countries and operates a global service network. The Company is listed on the London Stock Exchange and is a constituent of the FTSE4Good Index. Further information is available at www.imiplc.com.

 

References to adjusted figures reflect figures as reported to management and do not include the impact of adjusting items. References to organic changes are on a constant currency basis and exclude disposals and acquisitions.

 

IMI plc is registered in England No. 714275. Its legal entity identifier ('LEI') number is 2138002W9Q21PF751R30.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDDLFBLFLXFBD
Date   Source Headline
12th Apr 20241:49 pmRNSDirector/PDMR Shareholding
10th Apr 20241:42 pmRNSDirector/PDMR Shareholding
2nd Apr 20241:50 pmRNSTotal Voting Rights
28th Mar 20249:11 amRNSAnnual Financial Report
27th Mar 20244:48 pmRNSDirector/PDMR Shareholding
20th Mar 202411:37 amRNSDirector/PDMR Shareholding
14th Mar 20248:58 amRNSRetail Investor Webinar
13th Mar 20241:58 pmRNSDirector/PDMR Shareholding
1st Mar 20241:58 pmRNSTotal Voting Rights
1st Mar 20241:57 pmRNSDirector Declaration
1st Mar 20247:00 amRNSPreliminary Results
29th Feb 202410:09 amRNSDirectorate Change
27th Feb 20248:54 amRNSHolding(s) in Company
14th Feb 202411:35 amRNSDirector/PDMR Shareholding
1st Feb 202411:28 amRNSTotal Voting Rights
30th Jan 202411:02 amRNSDirectorate Change
10th Jan 20241:01 pmRNSDirector/PDMR Shareholding
2nd Jan 202411:35 amRNSBlock listing Interim Review
2nd Jan 202411:04 amRNSTotal Voting Rights
19th Dec 20239:55 amRNSDirector/PDMR Shareholding
13th Dec 20233:41 pmRNSDirector/PDMR Shareholding
5th Dec 20239:28 amRNSDirector Declaration
1st Dec 20231:30 pmRNSTotal Voting Rights
15th Nov 20231:42 pmRNSDirector/PDMR Shareholding
9th Nov 20237:01 amRNSHistorical Financial Information
9th Nov 20237:00 amRNSInterim Management Statement
1st Nov 202312:42 pmRNSTotal Voting Rights
11th Oct 20233:20 pmRNSDirector/PDMR Shareholding
2nd Oct 20231:19 pmRNSTotal Voting Rights
13th Sep 20233:32 pmRNSDirector/PDMR Shareholding
1st Sep 202311:29 amRNSTotal Voting Rights
10th Aug 20234:53 pmRNSDirector/PDMR Shareholding
10th Aug 20234:38 pmRNSDirector/PDMR Shareholding
9th Aug 20232:34 pmRNSDirector/PDMR Shareholding
1st Aug 202310:16 amRNSTotal Voting Rights
31st Jul 20231:52 pmRNSDirector/PDMR Shareholding
28th Jul 20237:00 amRNSInterim Results
12th Jul 20231:13 pmRNSDirector/PDMR Shareholding
3rd Jul 20232:58 pmRNSBlock listing Interim Review
3rd Jul 20232:41 pmRNSTotal Voting Rights
26th Jun 20234:39 pmRNSHolding(s) in Company
14th Jun 202310:48 amRNSDirector/PDMR Shareholding
8th Jun 20233:18 pmRNSDirector/PDMR Shareholding
1st Jun 20231:51 pmRNSTotal Voting Rights
22nd May 202310:18 amRNSDirectorate Change
11th May 202311:49 amRNSHolding(s) in Company
10th May 20232:40 pmRNSDirector/PDMR Shareholding
4th May 20231:05 pmRNSResult of AGM
4th May 20237:00 amRNSInterim Management Statement
2nd May 20232:46 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.